The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $50.0, a high ...

Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 ...

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of 4.65% and 1.13%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the ...

Plants that always come to mind for providing almost constant summer color are Blackfoot Daisy (Melampodium leucanthum) and ...

Spring is here, so we had to compile a list of baby names inspired by flowers. Not only are these names sweet, but some are ...

Dianthus Therapeutics (NASDAQ:DNTH), a biopharmaceutical company listed on the NASDAQ and part of the s&p 500 index ...

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, announced ...

NEW YORK and WALTHAM, Mass. - Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a biotech firm focused on antibody complement therapeutics for autoimmune diseases, has announced the completion of ...

Annuals aren't always known for their long-lasting blooms, but there are some exceptions. Here are the top 6 eye-catching ...

NEW YORK and WALTHAM, Mass. - Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a biotech firm focused on antibody complement therapeutics for autoimmune diseases, has announced the completion of patient ...